Inactive Instrument

Analyst Reco. Qiagen Nasdaq

Equities

Invest Securities Raises Qiagen PT, Maintains Neutral Rating	06-19	MT
UBS Raises Qiagen Price Target to $46 From $44, Maintains Neutral Rating	06-18	MT
JPMorgan Raises Price Target on Qiagen to $54 From $52, Maintains Overweight Rating	06-18	MT
QIAGEN NV : Gets a Neutral rating from UBS	06-18	ZD
QIAGEN NV : Deutsche Bank reaffirms its Buy rating	06-18	ZD
QIAGEN NV : Berenberg remains its Buy rating	06-18	ZD
QIAGEN NV : Berenberg maintains a Buy rating	05-21	ZD
QIAGEN NV : Berenberg reaffirms its Buy rating	04-30	ZD
QIAGEN : A decent start to 2024; guidance unchanged	04-30
QIAGEN NV : Deutsche Bank reiterates its Buy rating	04-30	ZD
QIAGEN NV : Jefferies remains Neutral	04-30	ZD
QIAGEN NV : UBS remains Neutral	04-30	ZD
QIAGEN NV : UBS remains Neutral	04-30	ZD
QIAGEN NV : UBS sticks Neutral	04-30	ZD
QIAGEN NV : Deutsche Bank reiterates its Buy rating	04-16	ZD
QIAGEN NV : UBS reaffirms its Neutral rating	03-01	ZD
Morgan Stanley Upgrades Qiagen to Overweight From Equalweight, Adjusts Price Target to $49.48 From $51	02-16	MT
QIAGEN NV : Berenberg reiterates its Buy rating	02-16	ZD
QIAGEN NV : Deutsche Bank remains its Buy rating	02-14	ZD
QIAGEN NV : JP Morgan reiterates its Buy rating	02-08	ZD

No results for this search

QIAGEN : A decent start to 2024; guidance unchanged

April 30, 2024 at 09:32 am